 And we realized that drug did not get approved for another 14 years for that specific indication. With her own diagnosis, Ahlstrom felt the clock was ticking. In multiple myeloma, the blood cancer that I have, I don't have the luxury of waiting another 30 years, 50 years. I don't have that.